ReviewInternational journal of molecular sciences2026
The Role of the OSM/OSMRβ Axis in Chronic Liver Disease Progression and Hepatocellular Carcinoma Development: A Focus on MASLD/MASH.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents the emerging leading cause of Chronic Liver Disease (CLD) worldwide, with a global prevalence of approximately 30% in the general population that parallels global rates of obesity and Type 2 Diabetes (T2D). Although two drugs (Resmetirom and Semaglutide) have been recently approved for clinical use, their ability to block or slow down disease progression to metabolic dysfunction-associated Steatohepatitis (MASH) and liver fibrosis is limited to a subset of patients, and no data are available at present for the efficacy of these drugs in compensated cirrhosis or in relation to hepatocellular carcinoma (HCC) development. Moreover, there is a lack of reliable biomarkers able to identify MASH patients at risk of disease progression and/or HCC development. In line with the knowledge that pro-inflammatory cytokines play a key role in MASLD/MASH progression and HCC development, in this review, we will discuss the role in this disease and other CLDs of Oncostatin M (OSM), a cytokine belonging to the IL6 family, and of pathways involving OSM and its receptor β (OSM/OSMRβ axis). OSM and related pathways are emerging as selective in sustaining disease progression by promoting chronic inflammation and fibrogenesis. The OSM/OSMRβ axis is proposed to be involved in MASH-related HCC development by affecting proliferation, angiogenesis, invasiveness and metastasis as well as by reshaping the MASH-related tumor immune microenvironment. OSM and the OSM/OSMRβ axis are emerging as a candidate biomarker and putative MASH-related therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.